Dr. Peter J. Ruane, MD

Dr. Ruane practices at Usa Advanced Care Surgical Center in Los Angeles, California.

Dr. Ruane's NPI, 1467640953, was assigned on October 9, 2007. Dr. Ruane graduated from University College of Dublin National Univ SOM in 1978. Dr. Ruane's California license number on file is A42947.

Dr. Ruane's primary practice is Usa Advanced Care Surgical Center, at 5901 W Olympic Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (323) 934-8877.

Dr. Ruane's primary practice is Usa Advanced Care Surgical Center in Los Angeles, California. Dr. Ruane is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Peter J. Ruane, MD. Dmand AI also links Dr. Ruane to 2 more home health agencies and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ruane practices, 4 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Ruane's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Ruane is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Ruane's licenses on file in 2 states: California and Minnesota.

Dmand AI lists acute skin infection, bronchitis, hiv/aids, pneumonia, shingles, UTI and yeast infection among the conditions Dr. Ruane treats.

CMS data shows 10,980 Medicare services from Dr. Ruane across 53 procedure codes in 2024, for 325 Medicare patients. Medicare paid $313,455 for them. Every service was in an office.

CMS counts 325 Medicare patients who saw Dr. Ruane in 2024. The largest group is 65 to 74, with 206 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ruane's median patient age at 54, with 13% women.

In 2024, Dr. Ruane wrote 1,368 Medicare Part D claims for 133 patients. 63% of them were for generic drugs. CMS names the drug for 757 of them, across 33 drugs with 11 or more claims each, at $1,333,927 in total drug cost. In 2023, CMS named 312 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Ruane for performance year 2024, reported individually. CMS lists Dr. Ruane as offering telehealth. CMS counts 12 procedures of removal of skin lesions by Dr. Ruane, more than 59% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Ruane, published from 2015 to 2021. 2018 was the busiest year, with 5. The most frequent topics are Adenine, Anti-HIV Agents and Emtricitabine. Dr. Ruane's most frequent co-authors are Edwin Dejesus, MD, Roger Nguyen Trinh, MD and Diana Marina Brainard, MD.

Dmand AI links Dr. Ruane to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Fibromyalgia, Hepatitis C, Chronic and HIV Infections. Open Payments lists research payments to Dr. Ruane that name 2 trials.

CMS Open Payments shows 1,643 general payments to Dr. Ruane from 48 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 54% of the total. Gilead Sciences, Inc. paid the most, $181,651. It also lists 90 research payments totaling $1,134,479 from 2016 to 2023, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Ruane, most recently CMS Stage 1 EHR in 2013.

Dr. Ruane graduated from University College of Dublin National Univ SOM in 1978.

Dr. Ruane is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.